Yes, Certain Groups Face Higher Risk
Patients with renal impairment are most vulnerable to acyclovir's neurological side effects, such as confusion, hallucinations, tremors, agitation, seizures, and coma. Acyclovir is primarily excreted by the kidneys; impaired function causes drug accumulation, elevating neurotoxicity risk.[1][2]
Why Renal Problems Increase Risk
In those with reduced kidney function (e.g., creatinine clearance below 50 mL/min), dose adjustments are required to prevent buildup. Studies show neurotoxicity incidence rises sharply here—up to 12-28% in severe cases like dialysis patients—versus under 1% in healthy individuals. Symptoms often appear within 24-72 hours of high-dose IV therapy.[1][3]
Other At-Risk Populations
- Elderly patients: Age-related kidney decline amplifies accumulation; they're overrepresented in case reports.[2][4]
- Dehydrated or volume-depleted individuals: Reduced urine output worsens clearance, especially during acute infections like herpes zoster.[1]
- Neonates and infants: Immature kidneys heighten risk, particularly with high-dose treatment for neonatal herpes.[5]
- Those on nephrotoxic drugs: Combinations like aminoglycosides or amphotericin B compound impairment.[2]
HIV patients or transplant recipients on immunosuppressants may also see elevated rates due to frequent renal issues or high dosing needs.[3]
How Symptoms Develop and Resolve
Neurotoxicity stems from acyclovir's penetration into cerebrospinal fluid, exacerbated by high plasma levels. Symptoms are reversible in most cases with hemodialysis, which clears 60% of the drug quickly—full recovery often within days.[1][4]
Prevention in High-Risk Groups
Guidelines recommend:
- Baseline creatinine checks and dosing by renal function (e.g., halve IV dose if CrCl 25-50 mL/min).[2]
- Hydration to boost clearance.
- Monitoring for early neurologic changes, especially in elderly or renally impaired patients.[1]
| Population | Key Risk Factor | Reported Incidence |
|------------|----------------|-------------------|
| Renal impairment (CrCl <10 mL/min) | Drug accumulation | 12-28% [3] |
| Elderly (>65 years) | Declining GFR | 2-5x higher [4] |
| Neonates | Immature kidneys | Case series dominant [5] |
Rare Cases Beyond Renal Issues
Isolated reports link neurotoxicity to overdose, very high doses (e.g., >15 mg/kg IV), or hypersensitivity, even with normal kidneys. Genetic factors like poor metabolizers are hypothesized but unproven.[2]
Sources
[1]: Lexicomp - Acyclovir Neurotoxicity
[2]: UpToDate - Acyclovir: Adverse Effects
[3]: PubMed - Acyclovir-Induced Neurotoxicity in CKD
[4]: Clinical Infectious Diseases - Review of Acyclovir Neurotoxicity
[5]: Pediatrics - Neonatal Acyclovir Safety